spacer
home > subscribe to IPT
IPT SUBSCRIPTION FORM

Title:
First Name:
Last Name:
Company Name:
Address 1:
Address 2:
Town / City: ZIP / Post Code:
Country: Other:
Tel.: E-mail:

Please answer the following questions:

1. What is your Primary Field of Work/Business/Industry?



Other:

2. What is your Job Title?



Other:
Additional Information:
Please repeat the security code (not case sensitive)*
   
spacer
News and Press Releases

Significant improvement in overall survival with ERLEADA®▼ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer

BEERSE, BELGIUM, May 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA®▼ (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.1 Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Programme (Abstract #5516) beginning on Friday 29th May.
More info >>

 
Industry Events

Evolution Summit

20-22 July 2020, The Ritz Carlton, Fort Lauderdale, FL

The 22nd Evolution Summit is the premium forum bringing leading drug development executives and solution providers together. As an invitation-only event, taking place behind closed doors, the Summit offers an intimate environment for a focused discussion of key new drivers shaping drug development.
More info >>

.
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement